Effective market access requires more than demonstrating clinical value. Explore how payer decisions shape coverage, evidence needs and engagement throughout the product lifecycle.
ISPOR 2026 research from Magnolia Market Access highlights why the right claims data source depends on the evidence question, outcome, and decision it needs to support.
Real-world evidence can help reduce uncertainty in access decisions by addressing questions clinical trials may not fully answer, including long-term outcomes, real-world utilization, and system-level impact.
Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
How AI-driven EMR analysis helped identify high-risk cardiovascular patients and support earlier intervention.
How a biotechnology company used real-world data analysis to uncover cost drivers and validate the economic impact of EVLP.
A small medical device company engaged Magnolia Market Access to strengthen its evidence strategy and value messaging for an innovative oncology device. Despite strong clinical results, the company needed to address evidence gaps and ensure its value story resonated with payers and providers.
This case study explores how a small pharmaceutical company utilized real-world evidence (RWE) to calculate the national incidence of a rare disease.
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.